Norway Cancer Biomarker Market Size & Outlook, 2026-2033
Related Markets
Norway cancer biomarker market highlights
- The Norway cancer biomarker market generated a revenue of USD 163.1 million in 2025 and is expected to reach USD 355.2 million by 2033.
- The Norway market is expected to grow at a CAGR of 10.3% from 2026 to 2033.
- In terms of segment, lung cancer was the largest revenue generating type in 2025.
- Lung Cancer is the most lucrative type segment registering the fastest growth during the forecast period.
Cancer biomarker market data book summary
| Market revenue in 2025 | USD 163.1 million |
| Market revenue in 2033 | USD 355.2 million |
| Growth rate | 10.3% (CAGR from 2026 to 2033) |
| Largest segment | Lung cancer |
| Fastest growing segment | Lung Cancer |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Breast Cancer, Prostate Cancer, Colorectal Cancer, Cervical Cancer, Liver Cancer, Lung Cancer |
Other key industry trends
- In terms of revenue, Norway accounted for 0.6% of the global cancer biomarker market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Europe, Germany cancer biomarker market is projected to lead the regional market in terms of revenue in 2033.
- Norway is the fastest growing regional market in Europe and is projected to reach USD 355.2 million by 2033.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cancer Biomarker Market Scope
Cancer Biomarker Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Abbott | View profile | - | - | - |
| F. Hoffmann-La Roche Ltd. | View profile | - | - | - |
| CanSino Biologics Inc Class H | View profile | 1494 | 185 South Avenue, 401-420, 4th Floor, Biomedical Park, TEDA West District, Tianjin, China, People's Republic of, | https://www.cansinotech.com |
| Hologic Inc | View profile | 6990 | 250 Campus Drive, Marlborough, MA, United States, 01752 | http://www.hologic.com |
| Qiagen NV | View profile | 5900 | Hulsterweg 82, Venlo, LI, Netherlands, 5912 PL | https://www.qiagen.com |
| Agilent Technologies Inc | View profile | 17700 | 5301 Stevens Creek Boulevard, Santa Clara, CA, United States, 95051 | https://www.agilent.com |
| Illumina Inc | View profile | 9300 | 5200 Illumina Way, San Diego, CA, United States, 92122 | https://www.illumina.com |
| Thermo Fisher Scientific Inc | View profile | 122000 | 168 Third Avenue, Waltham, MA, United States, 02451 | https://www.thermofisher.com |
| Merck KGaA | View profile | 62345 | Frankfurter Strasse 250, Darmstadt, HE, Germany, 64293 | https://www.emdgroup.com |
Norway cancer biomarker market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cancer biomarker market will help companies and investors design strategic landscapes.
Lung cancer was the largest segment with a revenue share of 24.1% in 2025. Horizon Databook has segmented the Norway cancer biomarker market based on breast cancer, prostate cancer, colorectal cancer, cervical cancer, liver cancer, lung cancer covering the revenue growth of each sub-segment from 2021 to 2033.
Reasons to subscribe to Norway cancer biomarker market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Norway cancer biomarker market databook
-
Our clientele includes a mix of cancer biomarker market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Norway cancer biomarker market , including forecasts for subscribers. This country databook contains high-level insights into Norway cancer biomarker market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Partial client list
Norway Type - Cancer Biomarker Market size, 2025 - 2033 (US$M)
Norway Cancer Biomarker Market Outlook Share, 2025 & 2033 (US$M)
Related industry reports
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
